These effects are more marked in people with type 2 diabetes where glucagon secretion, which is estimated using recently developed methodology (13), is inappropriate for the degree of hyperglycemia and impairs suppression of endogenous glucose production. The gene discussed is GCG; the disease is type 2 diabetes mellitus.